Structure And Interactions Of The Malarial Vaccine Candidate AMA1
Funder
National Health and Medical Research Council
Funding Amount
$351,000.00
Summary
Malaria remains one the most lethal infectious diseases in the world today. It is directly responsible for 1-2 million deaths annually, many of these in children under 5 years of age. More than 300 million clinical cases are reported annually and over 40% of the global population (in excess of 2 billion people) are at risk. There is an urgent need for a vaccine against this disease, particularly because of the recent increase in forms of the parasite resistant to many of the best anti-malarial d ....Malaria remains one the most lethal infectious diseases in the world today. It is directly responsible for 1-2 million deaths annually, many of these in children under 5 years of age. More than 300 million clinical cases are reported annually and over 40% of the global population (in excess of 2 billion people) are at risk. There is an urgent need for a vaccine against this disease, particularly because of the recent increase in forms of the parasite resistant to many of the best anti-malarial drugs. AMA1 is an asexual stage antigen and a leading vaccine candidate. Little is known about the function of this protein, but it has been proposed to play a role in invasion of red blood cells. A clearer understanding of the structure of parasite antigens such as AMA1 that induce a protective response in infected individuals would provide a stimulus to research into recombinant antigens as vaccines and a deeper understanding of host-parasite interactions. The aims of this project are to determine the three-dimensional structures of the three major structural domains of AMA1 and of the complete AMA1 antigen. We shall also determine the structures, both in aqueous solution and bound to AMA1, of small peptides identified by phage display as being capable of binding to AMA1 and blocking parasite entry into red blood cells. The overall goal of this work is to determine the structure of AMA1 and define the structural basis for its interaction with small peptides capable of blocking its activity as well as the structural features necessary for AMA1 to react with protective antibodies. The structure of AMA1 will provide a molecular basis for the design of engineered antigens capable of eliciting a protective immune response against AMA1. The inhibitory peptide structures will likewise provide a molecular basis for the design of non-peptidic blockers of AMA1. Either or both of these may be useful therapeutics leads in the fight against malaria.Read moreRead less
Structure And Interactions Of The Malarial Surface Antigen AMA1
Funder
National Health and Medical Research Council
Funding Amount
$242,545.00
Summary
Malaria remains one of the most serious infectious diseases in the world today, being responsible for 1-2 million deaths annually. There is an urgent need for a vaccine against this disease, particularly because of the recent increase in forms of the parasite resistant to many of the best anti-malarial drugs. A clearer understanding of the structure of antigens in the parasite that induce a protective response in infected individuals would provide a stimulus to research into recombinant antigens ....Malaria remains one of the most serious infectious diseases in the world today, being responsible for 1-2 million deaths annually. There is an urgent need for a vaccine against this disease, particularly because of the recent increase in forms of the parasite resistant to many of the best anti-malarial drugs. A clearer understanding of the structure of antigens in the parasite that induce a protective response in infected individuals would provide a stimulus to research into recombinant antigens as vaccines and a deeper understanding of the host-parasite interaction. AMA1 is an asexual stage antigen and a leading vaccine candidate. Little is known about the function of this protein, but it has been proposed to play a role in invasion of red blood cells. The specific aims of this project are to determine the three-dimensional structures of the three major structural domains of AMA1 and of the complete AMA1 ectodomain. The interaction of one or more of these domains with Fab fragments of protective antibodies raised against intact AMA1 will then be investigated. We also intend to determine the conformations, both in aqueous solution and bound to AMA1, of oligopeptides identified by phage display as binding to AMA1 and blocking its binding to red blood cells. The overall goals of this work are to determine the structure of AMA1 and to define the structural basis for its interaction with antibodies and small peptides that are capable of blocking its activity. This information will provide a molecular basis for the design of either synthetic antigens capable of eliciting a protective immune response against AMA1 or peptidomimetic inhibitors of AMA1. Either or both of these may be useful in the prevention or treatment of malaria.Read moreRead less
The Molecular Basis Of HLA-linked Drug Hypersensivity Reactions
Funder
National Health and Medical Research Council
Funding Amount
$683,040.00
Summary
Adverse drug reactions are one of the leading causes of death in hospitalised patients. We have discovered a new mechanism that links these reactions to recognition of drug induced changes in immunological self, resulting from interactions of drugs with immune receptors. This project probes the generality of this mechanism by examining the basis of life threatening reactions to drugs used to treat epilepsy (carbamazepine), gout (allopurinol), HIV (Nevirapine) and towards aspirin a commonly used ....Adverse drug reactions are one of the leading causes of death in hospitalised patients. We have discovered a new mechanism that links these reactions to recognition of drug induced changes in immunological self, resulting from interactions of drugs with immune receptors. This project probes the generality of this mechanism by examining the basis of life threatening reactions to drugs used to treat epilepsy (carbamazepine), gout (allopurinol), HIV (Nevirapine) and towards aspirin a commonly used pharmaceutical.Read moreRead less
Understanding The Complexity Of Antigen Presentation
Funder
National Health and Medical Research Council
Funding Amount
$774,540.00
Summary
I have developed and established the use of mass spectrometry to identify and quantitate ligands of antigen presenting molecules to understand the breadth of immune responses in a variety of human disease states including autoimmunity, cancer, infection and allergy. By embedding the technology in disease focussed research programs I will define the molecular bases of these diseases and the important immunological targets that will provide new avenues for therapeutic development and vaccines.
Antibodies Against Erythrocyte Invasion Ligands Of Plasmodium Falciparum And Protection From Malaria
Funder
National Health and Medical Research Council
Funding Amount
$358,184.00
Summary
Malaria is a leading cause of childhood death globally. Malaria parasites infect red blood cells and multiply inside them, resulting in severe illness if untreated. Currently there is no vaccine available and effective treatments are limited. In studies of children in Africa and PNG, we aim to identify immune responses that block infection and growth of malaria in the blood. With this knowledge, vaccines can be designed that target malaria to prevent serious illness and death.